Month: July 2017

Lexington Biosciences Announces Closing of Private Placement

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES  VANCOUVER, BC – (July 28, 2017) – Lexington Biosciences, Inc. (CSE: LNB)( OTC: LXGTF) (the “Company” or “Lexington”), a development-stage medical device company operating within the healthcare industry, is pleased to announce, further to its news release of

Read More

Lexington Biosciences Announces DTC Eligibility of LXGTF Common Shares on OTCQB

VANCOUVER, BC–(Jul 25, 2017) – Lexington Biosciences, Inc. (CSE: LNB) (CNSX: LNB) (OTCQB: LXGTF) (the “Company” or “Lexington”), a development-stage medical device company operating within the healthcare industry, is pleased to announce it has received processing approval from The Depository Trust Company (“DTC”) of New York, NY and is now DTC eligible. The Depository Trust Company (DTC) is a subsidiary

Read More

Lexington Biosciences Introduces Medical Advisory Board

Advisory team prepares to move HeartSentry through clinical studies VANCOUVER, BC–(Jul 20, 2017) – Lexington Biosciences, Inc. (CSE: LNB) (CNSX: LNB) (OTCQB: LXGTF) (the “Company” or “Lexington”), a development-stage medical device company operating within the healthcare industry, in preparation for the commencement of its HeartSentry clinical studies, today wishes to introduce the members of its Medical Advisory Board. The growing

Read More

Lexington Biosciences Commences Trading on OTC Markets as LXGTF and Introduces Key Board Members

VANCOUVER, BC–(Jul 6, 2017) – Lexington Biosciences, Inc. (CSE: LNB) (CNSX: LNB) (OTC PINK: LXGTF) (the “Company” or “Lexington”), a development-stage medical device company operating within the healthcare industry, is pleased to announce it has met the compliance requirements of the Financial Industry Regulatory Authority (FINRA) and has initiated price quotation on OTC Link under the ticker symbol: LXGTF. In

Read More

Archives

Categories

Newsletter Updates

If you haven’t already done so, signup here to receive future editions and the latest company news direct to your inbox.

Latest News